Katharina M Scheurlen1, Dylan L Snook1, Mary N Walter1, Cheyenne N Cook1, Casey R Fiechter1, Jianmin Pan2, Robert J Beal1, Susan Galandiuk3. 1. Department of Surgery, Price Institute of Surgical Research, University of Louisville, Louisville, KY. 2. Biostatistics Shared Facility, James Graham Brown Cancer Center, University of Louisville, Louisville, KY. 3. Department of Surgery, Price Institute of Surgical Research, University of Louisville, Louisville, KY. Electronic address: susan.galandiuk@louisville.edu.
Abstract
BACKGROUND: Along with the rising incidence of obesity, there has been an increase in patients diagnosed with early-onset colorectal cancer (<50 years old). In colorectal cancer, worse patient survival is associated with certain cytokine expression and downregulation of peroxisome proliferator activated receptor gamma expression. The effects of the obesity hormone leptin and macrophage-specific metabolite itaconate on these mechanisms are poorly understood. We investigated their impact on peroxisome proliferator activated receptor gamma and macrophage cytokine expression in vitro. METHODS: M2-like macrophages were treated with either leptin, 4-octyl itaconate, or dimethyl itaconate in a dose- and time-dependent manner. Gene expression after treatment with 4 doses (D1-4) of each compound was analyzed at 4 time points (3, 6, 18, and 24 hours). RESULTS: Peroxisome proliferator activated receptor gamma was downregulated after 4-octyl itaconate treatment at 18 hours (FC -32.67, P ≤ .001). Interleukin-8 was upregulated after leptin and dimethyl itaconate treatment at 6 hours (FC 26.35 at D4, P ≤ .001, and FC 23.26 at D3, P = .006). Dimethyl itaconate upregulated IL-1β at 24 hours (FC 18.00 at D4, P ≤ .001). Tumor necrosis factor-α showed maximum downregulation after 4-octyl itaconate at 18 hours (FC -103.25 at D4, P ≤ .001). CONCLUSIONS: Itaconate downregulates peroxisome proliferator activated receptor gamma as a tumor-suppressing factor and upregulates anti-inflammatory cytokines in M2-like macrophages. Itaconate provides a link between obesity and colorectal cancer and may be a key regulator in early-onset colorectal cancer.
BACKGROUND: Along with the rising incidence of obesity, there has been an increase in patients diagnosed with early-onset colorectal cancer (<50 years old). In colorectal cancer, worse patient survival is associated with certain cytokine expression and downregulation of peroxisome proliferator activated receptor gamma expression. The effects of the obesity hormone leptin and macrophage-specific metabolite itaconate on these mechanisms are poorly understood. We investigated their impact on peroxisome proliferator activated receptor gamma and macrophage cytokine expression in vitro. METHODS: M2-like macrophages were treated with either leptin, 4-octyl itaconate, or dimethyl itaconate in a dose- and time-dependent manner. Gene expression after treatment with 4 doses (D1-4) of each compound was analyzed at 4 time points (3, 6, 18, and 24 hours). RESULTS: Peroxisome proliferator activated receptor gamma was downregulated after 4-octyl itaconate treatment at 18 hours (FC -32.67, P ≤ .001). Interleukin-8 was upregulated after leptin and dimethyl itaconate treatment at 6 hours (FC 26.35 at D4, P ≤ .001, and FC 23.26 at D3, P = .006). Dimethyl itaconate upregulated IL-1β at 24 hours (FC 18.00 at D4, P ≤ .001). Tumor necrosis factor-α showed maximum downregulation after 4-octyl itaconate at 18 hours (FC -103.25 at D4, P ≤ .001). CONCLUSIONS: Itaconate downregulates peroxisome proliferator activated receptor gamma as a tumor-suppressing factor and upregulates anti-inflammatory cytokines in M2-like macrophages. Itaconate provides a link between obesity and colorectal cancer and may be a key regulator in early-onset colorectal cancer.
Authors: Hisham Hussan; Arsheya Patel; Melissa Le Roux; Zobeida Cruz-Monserrate; Kyle Porter; Steven K Clinton; John M Carethers; Kerry S Courneya Journal: Clin Transl Gastroenterol Date: 2020-04 Impact factor: 4.488
Authors: Jonathan M Weiss; Luke C Davies; Megan Karwan; Lilia Ileva; Michelle K Ozaki; Robert Ys Cheng; Lisa A Ridnour; Christina M Annunziata; David A Wink; Daniel W McVicar Journal: J Clin Invest Date: 2018-07-30 Impact factor: 14.808
Authors: N Chaput; M Svrcek; A Aupérin; C Locher; F Drusch; D Malka; J Taïeb; D Goéré; M Ducreux; V Boige Journal: Br J Cancer Date: 2013-07-18 Impact factor: 7.640
Authors: Ho Won Kim; A-Reum Yu; Ji Won Lee; Hoe Sun Yoon; Byung Soo Lee; Hwan-Woo Park; Sung Ki Lee; Young Ik Lee; Jake Whang; Jong-Seok Kim Journal: Int J Mol Sci Date: 2022-04-15 Impact factor: 6.208